Synthetic Biologics Inc (NYSEAMERICAN:SYN) Short Interest Update

Synthetic Biologics Inc (NYSEAMERICAN:SYN) was the target of a large decline in short interest in December. As of December 29th, there was short interest totalling 4,416,270 shares, a decline of 9.7% from the December 15th total of 4,891,688 shares. Based on an average trading volume of 749,882 shares, the days-to-cover ratio is currently 5.9 days. Currently, 3.8% of the shares of the stock are short sold.

Shares of Synthetic Biologics (SYN) opened at $0.50 on Thursday. The company has a market capitalization of $67.43, a price-to-earnings ratio of -2.27 and a beta of 1.13. Synthetic Biologics has a twelve month low of $0.41 and a twelve month high of $1.05.

Synthetic Biologics (NYSEAMERICAN:SYN) last released its quarterly earnings data on Wednesday, November 1st. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.10).

Several research analysts recently issued reports on SYN shares. Zacks Investment Research downgraded Synthetic Biologics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. BidaskClub downgraded Synthetic Biologics from a “hold” rating to a “sell” rating in a report on Saturday, November 4th.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/01/18/synthetic-biologics-inc-syn-short-interest-update.html.

About Synthetic Biologics

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply